While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented ...

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations.

Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales. Let's ...

Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.